FDA DEVELOPMENTS LIMITED


Summary


FDA DEVELOPMENTS LIMITED was set up on Thursday, January 18, 2018. Their current partial address is C/O MGB ACCOUNTANTS - SUITE 22 TRYM LODGE, 1 HENBURY ROAD and the company status is Active.

Credit Score


Latest Accounts Filed:

31/07/2022

Next Set of Accounts Due:

30/04/2024

Company Vitals


Company Name:

FDA DEVELOPMENTS LIMITED

Time in Business:

6 years

Company Number:

11157323

Current Status:

Active

Company Category:

Private Limited Company

Country of Origin:

United Kingdom

Principal Activity:

[68100] - Buying and selling of own real estate

Registered Address:

C/O MGB ACCOUNTANTS - SUITE 22 TRYM LODGE, 1 HENBURY ROAD
WESTBURY-ON-TRYM
BRISTOL
UNITED KINGDOM
BS9 3HQ

Filing History


Submission Date Type
Gazette notice compulsory 2024-04-09 GAZ1
Change to a person with significant control 2023-11-06 PSC04
Change registered office address company with date old address new address 2023-11-06 AD01
Change person director company with change date 2023-11-06 CH01
Accounts with accounts type total exemption full 2023-03-20 AA
Confirmation statement with no updates 2023-01-26 CS01
Change account reference date company previous extended 2022-09-28 AA01
Confirmation statement with no updates 2022-02-02 CS01
Accounts with accounts type total exemption full 2021-09-19 AA
Confirmation statement with no updates 2021-01-27 CS01
Accounts with accounts type total exemption full 2020-10-21 AA
Change registered office address company with date old address new address 2020-04-14 AD01
Confirmation statement with updates 2020-02-17 CS01
Accounts with accounts type total exemption full 2019-10-23 AA
Confirmation statement with updates 2019-01-18 CS01
Mortgage create with deed with charge number charge creation date 2018-06-11 MR01
Mortgage create with deed with charge number charge creation date 2018-06-11 MR01
Mortgage create with deed with charge number charge creation date 2018-04-13 MR01
Change person director company with change date 2018-02-06 CH01
Change to a person with significant control 2018-02-06 PSC04